Biofrontera Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M |
| Selling, general & administrative | $37.8M | $33.8M | $39.0M | $35.1M | $36.5M |
| Research and development | $3.7M | $2.1M | $77,000 | — | — |
| Operating expenses | $53.1M | $54.5M | $56.7M | $47.3M | $49.3M |
| Operating income | -$11.3M | -$17.2M | -$22.7M | -$18.6M | -$25.2M |
| Interest expense | — | — | $220,000 | $12,000 | $344,000 |
| Pretax income | -$10.5M | -$17.7M | -$20.1M | -$608,000 | -$37.7M |
| Income tax expense | $25,000 | $22,000 | $14,000 | $32,000 | $56,000 |
| Net income | -$10.5M | -$17.8M | -$20.1M | -$640,000 | -$37.7M |
| Balance Sheet | |||||
| Cash and equivalents | $6.4M | $5.9M | $1.3M | $17.2M | $24.5M |
| Current assets | $18.1M | $20.7M | $23.1M | $43.1M | $46.4M |
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M |
| Current liabilities | $11.9M | $12.0M | $18.1M | $20.9M | $13.8M |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M |
| Stockholders' equity | $10.5M | $4.4M | $4.8M | $23.9M | $11.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$13.4M | -$10.3M | -$24.9M | -$16.2M | -$26.7M |
| Depreciation and amortization | $138,000 | $421,000 | $86,000 | $101,000 | $122,000 |
| Stock-based compensation | $951,000 | $1.0M | $1.0M | $1.9M | $129,000 |
| Capital expenditure | $2,000 | $10,000 | $5,000 | $38,000 | — |
| Free cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | — |
| Impairments | $0 | $0 | — | — | — |
Shares outstanding 12.8M · Free float 26.1%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.